AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1600042 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 2.5 mg plus Domperidone 10 mg three times daily for 7 days
Number of subjects: 25
Study 1600042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 1600042 — intervention group
Group type: COMPARATOR
Intervention: Cisapride plus Placebo
Number of subjects: 25
Study 3917606 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 8
Study 3917606 — intervention group
Group type: COMPARATOR
Intervention: Combined chlorpheniramine and cimetidine
Number of subjects: 8
Study 31251375 — intervention group
Group type: EXPERIMENTAL
Intervention: Thirdhand smoke (THS) exposure for 3 hours
Number of subjects: 4
Study 31251375 — intervention group
Group type: COMPARATOR
Intervention: Clean air exposure for 3 hours
Number of subjects: 4
Study 31251375 — intervention group
Group type: EXPERIMENTAL
Intervention: THS exposure
Number of subjects: 4
Study 29428919 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo mother care
Number of subjects: 200
Study 29428919 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo mother care with Music therapy
Number of subjects: 200
Study 29428919 — intervention group
Group type: COMPARATOR
Intervention: Music therapy
Number of subjects: 200
Study 29428919 — intervention group
Group type: COMPARATOR
Intervention: Control (no additional intervention)
Number of subjects: 200
Study 25917211 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional foot orthoses (FFOs)
Number of subjects: 37
Study 25917211 — intervention group
Group type: COMPARATOR
Intervention: Sham control orthosis
Number of subjects: 37
Study 24658964 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg/day (IM400)
Number of subjects: 784
Study 24658964 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg/day (IM800)
Number of subjects: 784
Study 22440975 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 mg/kg dexamphetamine
Number of subjects: 44
Study 22440975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 20075953 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel vaccine adjuvant system
Number of subjects: 0
Study 20075953 — intervention group
Group type: COMPARATOR
Intervention: Standard HBV vaccine
Number of subjects: 0
Study 17914132 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary formulation of Camellia sinensis (green tea) capsules, twice a day for 3 months
Number of subjects: 0
Study 17914132 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules, twice a day for 3 months
Number of subjects: 0
Study 16168327 — intervention group
Group type: EXPERIMENTAL
Intervention: facemask with palatal expansion
Number of subjects: 46
Study 16168327 — intervention group
Group type: EXPERIMENTAL
Intervention: facemask without palatal expansion
Number of subjects: 46
Study 16168327 — intervention group
Group type: COMPARATOR
Intervention: observation
Number of subjects: 46
Study 12151613 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin care programme (educational programme and skin care policy)
Number of subjects: 375
Study 12151613 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 375
Study 9831059 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 217
Study 9831059 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac 150 mg
Number of subjects: 217
Study 9831059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 7924164 — intervention group
Group type: EXPERIMENTAL
Intervention: acute hyperinsulinaemic hypoglycaemia (60 m-units min-1 m-2, 2.5 mmol/l)
Number of subjects: 10
Study 7924164 — intervention group
Group type: EXPERIMENTAL
Intervention: prolonged hyperinsulinaemic hypoglycaemia (60 m-units min-1 m-2, 2.5 mmol/l)
Number of subjects: 10
Study 7924164 — intervention group
Group type: EXPERIMENTAL
Intervention: euglycaemia (4.5 mmol/l)
Number of subjects: 10
Study 7924164 — intervention group
Group type: COMPARATOR
Intervention: placebo control (saline)
Number of subjects: 10
Study 2506998 — intervention group
Group type: EXPERIMENTAL
Intervention: 125I-NovoSol Basal
Number of subjects: 8
Study 2506998 — intervention group
Group type: COMPARATOR
Intervention: 125I-Ultratard HM
Number of subjects: 8
Study 54631 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza-B vaccine
Number of subjects: 0
Study 54631 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccine)
Number of subjects: 0
Study 54631 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza-A vaccine (A/Hong Kong)
Number of subjects: 0
Study 54631 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural infection (Influenza-A)
Number of subjects: 0
Study 54631 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza-B H.I. antibody
Number of subjects: 0
Study 31372917 — intervention group
Group type: EXPERIMENTAL
Intervention: CX-DZ-II intelligent electroacupuncture instrument
Number of subjects: 160
Study 31372917 — intervention group
Group type: COMPARATOR
Intervention: Pre-existing electroacupuncture instrument
Number of subjects: 160
Study 31779179 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and calcium fortified yogurt (400 IU of vitamin D3 and 800 mg calcium daily for 3 months)
Number of subjects: 40
Study 31779179 — intervention group
Group type: COMPARATOR
Intervention: Non-fortified yogurt (300 mg calcium, no vitamin D3)
Number of subjects: 40
Study 31779179 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and calcium fortified yogurt
Number of subjects: 40
Study 30362038 — intervention group
Group type: EXPERIMENTAL
Intervention: High food availability
Number of subjects: 48
Study 30362038 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal food availability
Number of subjects: 48
Study 30362038 — intervention group
Group type: EXPERIMENTAL
Intervention: Low food availability
Number of subjects: 48
Study 30362038 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic conditions (low dissolved oxygen)
Number of subjects: 48
Study 30362038 — intervention group
Group type: EXPERIMENTAL
Intervention: Tail muscle tissue
Number of subjects: 48
Study 27670603 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin group
Number of subjects: 312
Study 27670603 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline group
Number of subjects: 312
Study 24120589 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransfusion drain
Number of subjects: 115
Study 24120589 — intervention group
Group type: COMPARATOR
Intervention: No drainage system
Number of subjects: 115
Study 22071502 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable Practice (VP)
Number of subjects: 33
Study 22071502 — intervention group
Group type: COMPARATOR
Intervention: Constant Practice (CP) at 30% of maximum speed
Number of subjects: 33
Study 22071502 — intervention group
Group type: COMPARATOR
Intervention: Constant Practice (CP) at 55% of maximum speed
Number of subjects: 33
Study 19349548 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of vincristine, cyclophosphamide, doxorubicin (VDC), and dactinomycin alternating with ifosfamide and etoposide (IE) over 48 weeks
Number of subjects: 478
Study 19349548 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-intensified regimen of vincristine, cyclophosphamide, doxorubicin (VDC), and dactinomycin alternating with ifosfamide and etoposide (IE) over 30 weeks
Number of subjects: 478
Study 19349548 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (standard and intensified)
Number of subjects: 478
Study 17764540 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 220 mg once-daily
Number of subjects: 2076
Study 17764540 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg once-daily
Number of subjects: 2076
Study 17764540 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous enoxaparin 40 mg once-daily
Number of subjects: 2076
Study 17764540 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Dabigatran 220 mg, Dabigatran 150 mg, Enoxaparin)
Number of subjects: 2076
Study 15139393 — intervention group
Group type: EXPERIMENTAL
Intervention: Pork meat diet (170 g pig meat/10 MJ per day, 106 +/- 13 microg Se/d)
Number of subjects: 12
Study 11456384 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched n-6 polyunsaturated fat diet (9.2% energy from linoleic acid) for 8 weeks
Number of subjects: 26
Study 11456384 — intervention group
Group type: COMPARATOR
Intervention: High monounsaturated or saturated fat diet for 8 weeks (control)
Number of subjects: 26
Study 9919621 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid supplementation at 0-100 mg/day for 14 weeks
Number of subjects: 21
Study 7750677 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol group (n = 20) treated by whole gut irrigation with a 5 L solution containing 40 g/L of mannitol
Number of subjects: 40
Study 7750677 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 40
Study 7750677 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol group (n = 20)
Number of subjects: 40
Study 7750677 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 3281488 — intervention group
Group type: COMPARATOR
Intervention: C25 (25 mg/kg chloroquine over 3 days)
Number of subjects: 138
Study 3281488 — intervention group
Group type: EXPERIMENTAL
Intervention: C50 (50 mg/kg chloroquine over 5 days)
Number of subjects: 138
Study 1363409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of hydrocortisone succinate, 100 mg bolus at time 0 followed by 250 mg in 250 ml saline for 120 min
Number of subjects: 5
Study 1363409 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of saline, 250 ml
Number of subjects: 5
Study 408839 — intervention group
Group type: EXPERIMENTAL
Intervention: l-tryptophane 1 g
Number of subjects: 42
Study 408839 — intervention group
Group type: EXPERIMENTAL
Intervention: l-tryptophane 3 g
Number of subjects: 42
Study 408839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 31259734 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C9*2 allelic variant carriers
Number of subjects: 27
Study 31259734 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C9 *1/*3 or CYP2C9*1/*1 genotype carriers
Number of subjects: 27
Study 27085364 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous PRP therapy combined with a rehabilitation programme
Number of subjects: 75
Study 27085364 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation programme only
Number of subjects: 75
Study 24451919 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 54
Study 24451919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 24329929 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% sodium hypochlorite rinse
Number of subjects: 30
Study 24329929 — intervention group
Group type: COMPARATOR
Intervention: Water rinse (control)
Number of subjects: 30
Study 21966999 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin (300 μg)
Number of subjects: 36
Study 21966999 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 36
Study 19363974 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond (CS3)
Number of subjects: 6
Study 19363974 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop (ADP)
Number of subjects: 6
Study 19363974 — intervention group
Group type: EXPERIMENTAL
Intervention: iBond (iB)
Number of subjects: 6
Study 19363974 — intervention group
Group type: COMPARATOR
Intervention: Clearfil SE Bond (CSE)
Number of subjects: 6
Study 18637458 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid-free immunosuppression
Number of subjects: 650
Study 18637458 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid withdrawal
Number of subjects: 650
Study 14688150 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen‐progestin treatment (HRT)
Number of subjects: 0
Study 14688150 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies (HRT)
Number of subjects: 0
Study 14688150 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative reference group in observational studies
Number of subjects: 0
Study 14688150 — intervention group
Group type: COMPARATOR
Intervention: WHI Study (HRT)
Number of subjects: 0
Study 11451717 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g highly concentrated n‐3 fatty acids
Number of subjects: 300
Study 11451717 — intervention group
Group type: COMPARATOR
Intervention: Corn oil
Number of subjects: 300
Study 9540761 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (1 g every 8 h)
Number of subjects: 71
Study 9540761 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (2 g every 8 h) and Amikacin (15 mg/kg/day)
Number of subjects: 71
Study 9540761 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 71
Study 9540761 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime/Amikacin
Number of subjects: 71
Study 9540761 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study 8044157 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 184
Study 8044157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 2736055 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic human growth hormone (somatropin)
Number of subjects: 12
Study 2736055 — intervention group
Group type: COMPARATOR
Intervention: Control group (no somatropin)
Number of subjects: 12
Study 29406463 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir‐based antiretroviral therapy (ART)
Number of subjects: 161
Study 27422740 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (0.2, 0.5, 2.0, 6.0, or 10.0 mg/kg)
Number of subjects: 49
Study 27422740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 23689561 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium co-ingestion (15 mg/kg body mass)
Number of subjects: 10
Study 23689561 — intervention group
Group type: COMPARATOR
Intervention: Control meal (3 mg/kg body mass)
Number of subjects: 10
Study 22275153 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal distension
Number of subjects: 26
Study 22275153 — intervention group
Group type: COMPARATOR
Intervention: No rectal distension (control)
Number of subjects: 26
Study 20487528 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive educational intervention consisting of group sessions with standardised information about OAC therapy, lifestyle interactions, and INR monitoring.
Number of subjects: 200
Study 20487528 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 200
Study 18779274 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk intervention (3 servings/day, approximately 200 g per serving)
Number of subjects: 98
Study 18779274 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in milk consumption)
Number of subjects: 98
Study 18779274 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk intervention
Number of subjects: 98
Study 15759594 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-onset/increasers trajectory of aggression
Number of subjects: 0
Study 15759594 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-persistent trajectory of aggression
Number of subjects: 0
Study 15759594 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable low levels of aggression
Number of subjects: 0
Study 12422106 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper quartile of BMI (>30 kg/m(2))
Number of subjects: 104
Study 12422106 — intervention group
Group type: COMPARATOR
Intervention: Lower BMI (not specified)
Number of subjects: 104
Study 10365534 — intervention group
Group type: EXPERIMENTAL
Intervention: OHT recipients
Number of subjects: 17
Study 10365534 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary healthy men)
Number of subjects: 17
Study 8779381 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial pulse identification
Number of subjects: 554
Study 8779381 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid pulse identification
Number of subjects: 554
Study 8779381 — intervention group
Group type: COMPARATOR
Intervention: Airway management (laryngeal mask airway or tracheal tube)
Number of subjects: 554
Study 1516506 — intervention group
Group type: EXPERIMENTAL
Intervention: Single individual session
Number of subjects: 82
Study 1516506 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week behavior-oriented diabetes education and weight control group intervention
Number of subjects: 82
Study 1516506 — intervention group
Group type: EXPERIMENTAL
Intervention: Group intervention plus six individual follow-up sessions
Number of subjects: 82
Study 1516506 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes education-weight reduction intervention
Number of subjects: 82
Study 6372925 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0
Study 6372925 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (including antidepressant medication)
Number of subjects: 0
Study 29573098 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 116
Study 27608611 — intervention group
Group type: EXPERIMENTAL
Intervention: Active anodal tDCS over the supplementary motor area
Number of subjects: 22
Study 27608611 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 22
Study 24576532 — intervention group
Group type: EXPERIMENTAL
Intervention: paliperidone extended-release (3-12 mg)
Number of subjects: 136
Study 24576532 — intervention group
Group type: EXPERIMENTAL
Intervention: paliperidone extended-release
Number of subjects: 136
Study 24576532 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 136
Study 23018470 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy
Number of subjects: 179
Study 20357160 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (2, 4, and 16 mg/kg)
Number of subjects: 1321
Study 20357160 — intervention group
Group type: COMPARATOR
Intervention: Sugammadex
Number of subjects: 1321
Study 19101896 — intervention group
Group type: EXPERIMENTAL
Intervention: Petroleum jelly applied after each diaper change for 6 months
Number of subjects: 394
Study 16098297 — intervention group
Group type: EXPERIMENTAL
Intervention: Left bundle branch block (n = 48)
Number of subjects: 3053
Study 16098297 — intervention group
Group type: EXPERIMENTAL
Intervention: Right bundle branch block (n = 95)
Number of subjects: 3053
Study 16098297 — intervention group
Group type: COMPARATOR
Intervention: No bundle branch block (n = 2910)
Number of subjects: 3053
Study 12394420 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (serotonergic challenge)
Number of subjects: 36
Study 12394420 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (dopaminergic challenge)
Number of subjects: 36
Study 10068597 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel
Number of subjects: 1500
Study 10068597 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 1500
Study 10068597 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 1500
Study 7774513 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 30 mg twice daily, initiated post-operatively
Number of subjects: 0
Study 7774513 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg once daily starting preoperatively
Number of subjects: 0
Study 7774513 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 0
Study 2200994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (40 to 50 mg/kg/day for 10 days) in 3 divided doses (group 1)
Number of subjects: 73
Study 2200994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefatrizine (40 to 50 mg/kg/day for 10 days) in 3 divided doses (group 2)
Number of subjects: 73
Study 2200994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefatrizine (40 to 50 mg/kg/day for 10 days) in 2 divided doses (group 3)
Number of subjects: 73
Study 6269247 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline sulphate
Number of subjects: 10
Study 6269247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6269247 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study 6269247 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 10
Study 30819486 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmar warming with a warm, commercially available, air-activated heat pack
Number of subjects: 45
Study 30819486 — intervention group
Group type: COMPARATOR
Intervention: Control group with a deactivated heat pack
Number of subjects: 45
Study 27866188 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA) placement
Number of subjects: 36
Study 25678316 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-focused telephone-counseling program (up to 4 postnatal counseling calls using motivational interviewing)
Number of subjects: 250
Study 25678316 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 250
Study 23117350 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support (social integration, received social support, and negative social interactions)
Number of subjects: 173
Study 23117350 — intervention group
Group type: EXPERIMENTAL
Intervention: Center for Epidemiological Studies Depression Scale
Number of subjects: 173
Study 20825401 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction during the third task (answering questions about a medical case)
Number of subjects: 86
Study 20825401 — intervention group
Group type: COMPARATOR
Intervention: Control group (no distraction)
Number of subjects: 86
Study 20681373 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repairs (EVARs)
Number of subjects: 0
Study 20681373 — intervention group
Group type: COMPARATOR
Intervention: Open repair (OR)
Number of subjects: 0
Study 20681373 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall trend in EVARs
Number of subjects: 0
Study 17389151 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan and hydrochlorothiazide combination therapy, dosage and duration not specified.
Number of subjects: 0
Study 17389151 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, but implied as standard treatment or placebo.
Number of subjects: 0